Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Expert Consensus Document on Pulmonary Metastasectomy.

Handy JR, Bremner RM, Crocenzi TS, Detterbeck FC, Fernando HC, Fidias PM, Firestone S, Johnstone CA, Lanuti M, Litle VR, Kesler KA, Mitchell JD, Pass HI, Ross HJ, Varghese TK.

Ann Thorac Surg. 2019 Feb;107(2):631-649. doi: 10.1016/j.athoracsur.2018.10.028. Epub 2018 Nov 23. No abstract available.

PMID:
30476477
2.

Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies.

Campo M, Gerber D, Gainor JF, Heist RS, Temel JS, Shaw AT, Fidias P, Muzikansky A, Engelman JA, Sequist LV.

J Thorac Oncol. 2016 Nov;11(11):2022-2026. doi: 10.1016/j.jtho.2016.06.032. Epub 2016 Aug 20.

3.

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.

Cleary JM, Mamon HJ, Szymonifka J, Bueno R, Choi N, Donahue DM, Fidias PM, Gaissert HA, Jaklitsch MT, Kulke MH, Lynch TP, Mentzer SJ, Meyerhardt JA, Swanson RS, Wain J, Fuchs CS, Enzinger PC.

BMC Cancer. 2016 Jul 13;16:468. doi: 10.1186/s12885-016-2485-9.

4.

CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 31-2015. A 29-Year-Old Man with Thymoma, Diarrhea, and Weight Loss.

Fidias PM, Long AA, Fintelmann FJ, Zukerberg LR.

N Engl J Med. 2015 Oct 8;373(15):1458-67. doi: 10.1056/NEJMcpc1406663. No abstract available.

PMID:
26444733
5.

Lipodermatosclerosis secondary to pemetrexed use.

Shuster M, Morley K, Logan J, Sequist LV, Shaw A, Fidias P, Kroshinsky D.

J Thorac Oncol. 2015 Mar;10(3):e11-2. doi: 10.1097/JTO.0000000000000426. No abstract available.

6.

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.

Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, Gandhi L, Lynch TJ, Engelman JA, Jain RK.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1547-52. doi: 10.1073/pnas.1424024112. Epub 2015 Jan 20.

7.

Genotyping lung cancer is an investment in the future.

Azzoli CG, Engelman J, Fidias P, Gainor JF, Heist RS, Lamont EB, Lennes IT, Rosovsky RP, Sequist LV, Shaw AT, Temel JS.

J Clin Oncol. 2014 Nov 1;32(31):3576-7. doi: 10.1200/JCO.2014.56.6430. Epub 2014 Sep 8. No abstract available.

PMID:
25199750
8.

Occult primary, version 3.2014.

Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Jul;12(7):969-74.

PMID:
24994917
9.

Case records of the Massachusetts General Hospital. Case 17-2014. A 64-year-old man with chest pain and a pleural effusion.

Kradin RL, Fidias P, Digumarthy S, Mark EJ.

N Engl J Med. 2014 May 29;370(22):2132-40. doi: 10.1056/NEJMcpc1400835. No abstract available.

PMID:
24869724
10.

Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial.

Korst RJ, Bezjak A, Blackmon S, Choi N, Fidias P, Liu G, Marx A, Wright C, Mock S, Rutledge JR, Keshavjee S.

J Thorac Cardiovasc Surg. 2014 Jan;147(1):36-44, 46.e1. doi: 10.1016/j.jtcvs.2013.08.061. Epub 2013 Oct 15.

11.

Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer.

Lee MS, Mamon HJ, Hong TS, Choi NC, Fidias PM, Kwak EL, Meyerhardt JA, Ryan DP, Bueno R, Donahue DM, Jaklitsch MT, Lanuti M, Rattner DW, Fuchs CS, Enzinger PC.

Oncologist. 2013;18(3):281-7. doi: 10.1634/theoncologist.2012-0208. Epub 2013 Feb 21.

12.

Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer.

Choi NC, Chun TT, Niemierko A, Ancukiewicz M, Fidias PM, Kradin RL, Mathisen DJ, Lynch TJ, Fischman AJ.

Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):832-41. doi: 10.1007/s00259-013-2348-4. Epub 2013 Feb 12.

13.

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT.

Lancet Oncol. 2012 Oct;13(10):1011-9. doi: 10.1016/S1470-2045(12)70344-3. Epub 2012 Sep 4.

14.

A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.

Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV.

J Thorac Oncol. 2012 Oct;7(10):1602-8. doi: 10.1097/JTO.0b013e318262de4a.

15.

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W.

Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-33. doi: 10.1073/pnas.1203530109. Epub 2012 Jul 6.

16.

Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology.

Gridelli C, de Marinis F, Di Maio M, Ardizzoni A, Belani CP, Cappuzzo F, Ciardiello F, Fidias P, Paz-Ares L, Perrone F, Pirker R, De Petris L, Stahel R.

Lung Cancer. 2012 Jun;76(3):269-79. doi: 10.1016/j.lungcan.2011.12.011. Epub 2012 Jan 21. Review.

PMID:
22266040
17.

NCCN Clinical Practice Guidelines Occult primary.

Ettinger DS, Agulnik M, Cates JM, Cristea M, Denlinger CS, Eaton KD, Fidias PM, Gierada D, Gockerman JP, Handorf CR, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Shulman LN, Smerage JB, Varadhachary GR, Zager JS, Zhen WK; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Dec;9(12):1358-95.

PMID:
22157556
18.

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.

Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D.

Ann Oncol. 2011 Dec;22(12):2616-24. doi: 10.1093/annonc/mdr489. Epub 2011 Nov 9.

19.

DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer.

Alexander BM, Wang XZ, Niemierko A, Weaver DT, Mak RH, Roof KS, Fidias P, Wain J, Choi NC.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):164-71. doi: 10.1016/j.ijrobp.2011.05.033. Epub 2011 Oct 12.

PMID:
22000749
20.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA.

Sci Transl Med. 2011 Mar 23;3(75):75ra26. doi: 10.1126/scitranslmed.3002003.

21.

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.

Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS.

Ann Oncol. 2011 Jun;22(6):1367-73. doi: 10.1093/annonc/mdq604. Epub 2011 Jan 7.

22.

Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer.

Fidias P, Novello S.

J Clin Oncol. 2010 Dec 1;28(34):5116-23. doi: 10.1200/JCO.2010.30.7074. Epub 2010 Nov 1. Review.

23.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ.

N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448. Erratum in: N Engl J Med. 2011 Feb 10;364(6):588.

24.

Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV.

J Thorac Oncol. 2010 Nov;5(11):1855-8. doi: 10.1097/JTO.0b013e3181f0bee0.

25.

Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.

Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, Sequist LV, Temel JS, Fidias P, Brainerd V, Leopold L, Lynch TJ.

J Thorac Oncol. 2010 Oct;5(10):1637-43. doi: 10.1097/JTO.0b013e3181e8f4dc.

26.

Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer.

Sequist LV, Fidias P, Heist RS, Ostler P, Muzikansky A, Lynch TJ.

J Thorac Oncol. 2009 Sep;4(9):1170-3. doi: 10.1097/JTO.0b013e3181b28efe.

27.

Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.

Fidias P, Pennell NA, Boral AL, Shapiro GI, Skarin AT, Eder JP Jr, Kwoh TJ, Geary RS, Johnson BE, Lynch TJ, Supko JG.

J Thorac Oncol. 2009 Sep;4(9):1156-62. doi: 10.1097/JTO.0b013e3181b2793f.

28.

Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.

Sequist LV, Fidias PM, Temel JS, Kolevska T, Rabin MS, Boccia RV, Burris HA, Belt RJ, Huberman MS, Melnyk O, Mills GM, Englund CW, Caldwell DC, Keck JG, Meng L, Jones M, Brown GL, Edelman MJ, Lynch TJ.

J Thorac Oncol. 2009 Nov;4(11):1389-96. doi: 10.1097/JTO.0b013e3181b6b84b.

29.

Occult primary.

Ettinger DS, Agulnik M, Cristea M, Eaton K, Fidias PM, Gockerman JP, Hameed O, Handorf C, Harris EI, Jacobs CD, Javle M, Khushalani NI, Kvols L, Lenzi R, Lewis NL, Rashid A, Saltz L, Shulman LN, Zager JS, Zhen W.

J Natl Compr Canc Netw. 2008 Nov;6(10):1026-60. Review. No abstract available.

PMID:
19176200
30.

Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.

Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Earle CC, Kulke MH, Meyerhardt JA, Blaszkowsky LS, Zhu AX, Fidias P, Vincitore MM, Mayer RJ, Fuchs CS.

Ann Oncol. 2009 Mar;20(3):475-80. doi: 10.1093/annonc/mdn658. Epub 2009 Jan 12.

31.

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.

Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, Chen R, Hristova-Kazmierski M, Treat J, Obasaju CK, Marciniak M, Gill J, Schiller JH.

J Clin Oncol. 2009 Feb 1;27(4):591-8. doi: 10.1200/JCO.2008.17.1405. Epub 2008 Dec 15.

PMID:
19075278
32.

A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer.

Heist RS, Fidias P, Huberman M, Ardman B, Sequist LV, Temel JS, Lynch TJ.

J Thorac Oncol. 2008 Oct;3(10):1153-8. doi: 10.1097/JTO.0b013e318187273f.

33.

Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer.

George S, Kasimis BS, Cogswell J, Schwarzenberger P, Shapiro GI, Fidias P, Bukowski RM.

Clin Lung Cancer. 2008 May;9(3):160-5. doi: 10.3816/CLC.2008.n.024.

PMID:
18621626
34.

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.

Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA.

Cancer. 2008 Aug 15;113(4):808-14. doi: 10.1002/cncr.23617.

35.

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.

Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H.

J Clin Oncol. 2008 Mar 20;26(9):1465-71. doi: 10.1200/JCO.2007.14.7611.

PMID:
18349397
36.

Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors.

Wright CD, Choi NC, Wain JC, Mathisen DJ, Lynch TJ, Fidias P.

Ann Thorac Surg. 2008 Feb;85(2):385-9. doi: 10.1016/j.athoracsur.2007.08.051.

PMID:
18222230
37.

A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies.

Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G.

Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):204-11. doi: 10.1158/1055-9965.EPI-07-0470.

38.

A phase II study of gefitinib in patients with advanced thyroid cancer.

Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ.

Thyroid. 2008 Mar;18(3):317-23.

PMID:
17985985
39.

Non-small cell lung cancer in octogenarians: treatment practices and preferences.

Oxnard GR, Fidias P, Muzikansky A, Sequist LV.

J Thorac Oncol. 2007 Nov;2(11):1029-35.

40.

Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients.

Temel JS, Jackson VA, Billings JA, Dahlin C, Block SD, Buss MK, Ostler P, Fidias P, Muzikansky A, Greer JA, Pirl WF, Lynch TJ.

J Clin Oncol. 2007 Jun 10;25(17):2377-82.

PMID:
17557950
41.

Case records of the Massachusetts General Hospital. Case 16-2007. A 61-year-old man with a mediastinal mass.

Wright CD, Fidias P, Choi NC, Shepard JA, Hasserjian RP.

N Engl J Med. 2007 May 24;356(21):2185-93. No abstract available.

PMID:
17522403
42.

Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.

Sequist LV, Joshi VA, Jänne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ.

Oncologist. 2007 Jan;12(1):90-8.

PMID:
17285735
43.

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.

Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA.

J Clin Oncol. 2007 Mar 1;25(7):760-6. Epub 2007 Jan 16.

PMID:
17228019
44.

A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.

Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Cusack JC Jr.

Cancer. 2006 Dec 1;107(11):2688-97.

45.

Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH.

J Clin Oncol. 2006 Nov 1;24(31):5025-33.

PMID:
17075122
46.

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.

Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J Jr, Eder JP.

Cancer. 2006 Nov 15;107(10):2482-9.

47.

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-2006. A 43-year-old woman with painful nodules on the fingertips, shortness of breath, and fatigue.

Costenbader KH, Fidias P, Gilman MD, Qureshi A, Tambouret RH.

N Engl J Med. 2006 Sep 21;355(12):1263-72. No abstract available.

PMID:
16990390
48.

Epidermal growth factor receptor mutation testing in the care of lung cancer patients.

Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4403s-4408s. Review.

49.

Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.

Belani CP, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Fossella F; TAX 326 study group.

Lung Cancer. 2006 Aug;53(2):231-9. Epub 2006 Jun 19.

PMID:
16787687
50.

A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma.

Kulke MH, Muzikansky A, Clark J, Enzinger PC, Fidias P, Kinsella K, Michelini A, Fuchs CS.

Cancer Invest. 2006 Jun-Jul;24(4):346-50.

PMID:
16777685

Supplemental Content

Loading ...
Support Center